查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1881514

結核病診斷市場－全球產業規模、佔有率、趨勢、機會和預測，按檢測類型、最終用途、地區和競爭格局分類，2020-2030年預測

Tuberculosis Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By End-use, by Region, and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球結核病診斷市場規模為25.2億美元，預計2030年將以6.37%的複合年成長率成長至36.5億美元。全球結核病診斷市場致力於開發和應用用於識別結核分枝桿菌（結核病的病原體）的檢測方法和工具。全球結核病負擔沉重，以及對快速、精準檢測的迫切需求，是推動市場擴張的主要因素。技術進步，特別是分子檢測技術的進步，以及政府和組織對結核病防治日益成長的支持，進一步促進了市場成長。

市場概覽
預測期 2026-2030
2024年市場規模 25.2億美元
2030年市場規模 36.5億美元
2025-2030年複合年成長率 6.37%
成長最快的細分市場 診斷實驗室方法
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球結核病診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依檢測類型（放射線照相法、診斷實驗室方法、核酸檢測、噬菌體檢測、潛伏感染檢測、細胞激素檢測、藥物抗藥性檢測（DST）等）
    • 依最終用途（診斷實驗室、醫院和診所、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美結核病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲結核病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區結核病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲結核病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲結核病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球結核病診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Abbott Laboratories Inc.
  • Becton, Dickinson, and Company
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • BioMerieux SA
  • Hain Lifescience GmbH
  • QIAGEN NV
  • Cepheid
  • Hologic, Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 21521

The Global Tuberculosis Diagnostics Market, valued at USD 2.52 Billion in 2024, is projected to experience a CAGR of 6.37% to reach USD 3.65 Billion by 2030. The global tuberculosis diagnostics market develops and deploys tests and tools for identifying *Mycobacterium tuberculosis*, the causative agent of tuberculosis. Market expansion is driven by the significant global disease burden and the imperative for swift, precise detection. Technological advancements, particularly in molecular assays, alongside increasing governmental and organizational support for TB control, further stimulate growth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.52 Billion
Market Size 2030USD 3.65 Billion
CAGR 2025-20306.37%
Fastest Growing SegmentDiagnostic Laboratory Methods
Largest MarketNorth America

Key Market Drivers

The advancements in diagnostic technologies significantly propel the global tuberculosis diagnostics market by enhancing the speed, accuracy, and accessibility of testing solutions. Innovations such as molecular diagnostics, artificial intelligence powered imaging, and next-generation sequencing are transforming the diagnostic landscape, enabling earlier detection and more effective disease management. These technological improvements are particularly crucial for identifying latent tuberculosis infection and for deployment in diverse healthcare settings, from central laboratories to point-of-care environments. For instance, according to a Pharmacy Times news report, in April 2025, the FDA approved the Auto-Pure 2400 liquid handling platform with the T-SPOT. TB test, which allows laboratories to process up to 24 samples in under 3.5 hours for faster and more accurate latent TB diagnosis.

Key Market Challenges

Ensuring affordable and accessible advanced diagnostic technologies in resource-limited regions presents a significant impediment to the expansion of the Global Tuberculosis Diagnostics Market. The high capital expenditure required for advanced molecular diagnostic platforms, coupled with the recurring costs of reagents and consumables, creates substantial financial barriers for public health systems in high-burden, low-income countries. This economic constraint often leads to the underutilization or non-adoption of advanced diagnostic tools despite their accuracy and speed.

Key Market Trends

The rise in automated diagnostic platforms significantly drives the global tuberculosis diagnostics market by enhancing testing throughput and operational efficiency. These systems streamline laboratory workflows, minimizing manual intervention and accelerating sample processing, thereby reducing turnaround times for results. By the end of 2023, the Stop TB Partnership reported that cumulative global procurement of GeneXpert machines, representing key automated molecular platforms, exceeded 16,000 units across 167 countries, demonstrating substantial integration into diagnostic infrastructure. This increased capacity is crucial for managing high sample volumes in high-burden settings.

Key Market Players

  • Abbott Laboratories Inc.
  • Becton, Dickinson, and Company
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • BioMerieux SA
  • Hain Lifescience GmbH
  • QIAGEN NV
  • Cepheid
  • Hologic, Inc.

Report Scope:

In this report, the Global Tuberculosis Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tuberculosis Diagnostics Market, By Test Type:

  • Radiographic Method
  • Diagnostic Laboratory Methods
  • Nucleic Acid Testing
  • Phage Assay
  • Detection of Latent Infection
  • Cytokine Detection Assay
  • Detection of Drug Resistance (DST)
  • Others

Tuberculosis Diagnostics Market, By End-Use:

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Others

Tuberculosis Diagnostics Market, By Region:

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • MEA

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tuberculosis Diagnostics Market.

Available Customizations:

Global Tuberculosis Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tuberculosis Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Radiographic Method, Diagnostic Laboratory Methods, Nucleic Acid Testing, Phage Assay, Detection of Latent Infection, Cytokine Detection Assay, Detection of Drug Resistance (DST), others)
    • 5.2.2. By End-Use (Diagnostic Laboratories, Hospitals & Clinics, others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Tuberculosis Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By End-Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Tuberculosis Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By End-Use
    • 6.3.2. Canada Tuberculosis Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By End-Use
    • 6.3.3. Mexico Tuberculosis Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By End-Use

7. Europe Tuberculosis Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By End-Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Tuberculosis Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By End-Use
    • 7.3.2. France Tuberculosis Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By End-Use
    • 7.3.3. United Kingdom Tuberculosis Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By End-Use
    • 7.3.4. Italy Tuberculosis Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By End-Use
    • 7.3.5. Spain Tuberculosis Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By End-Use

8. Asia Pacific Tuberculosis Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By End-Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Tuberculosis Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By End-Use
    • 8.3.2. India Tuberculosis Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By End-Use
    • 8.3.3. Japan Tuberculosis Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By End-Use
    • 8.3.4. South Korea Tuberculosis Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By End-Use
    • 8.3.5. Australia Tuberculosis Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By End-Use

9. Middle East & Africa Tuberculosis Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By End-Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Tuberculosis Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By End-Use
    • 9.3.2. UAE Tuberculosis Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By End-Use
    • 9.3.3. South Africa Tuberculosis Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By End-Use

10. South America Tuberculosis Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By End-Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Tuberculosis Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By End-Use
    • 10.3.2. Colombia Tuberculosis Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By End-Use
    • 10.3.3. Argentina Tuberculosis Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Tuberculosis Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Becton, Dickinson, and Company
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. Thermo Fisher Scientific Inc.
  • 15.5. BioMerieux SA
  • 15.6. Hain Lifescience GmbH
  • 15.7. QIAGEN NV
  • 15.8. Cepheid
  • 15.9. Hologic, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer